Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension

Background The Seventh Report of the Joint National Committee (JNC 7) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends initial combination therapy for patients whose blood pressure (BP) is >20/10 mm Hg above goal. This study evaluated the efficacy and safety of initial combination therapy versus that of monotherapy in patients with stage 2 hypertension, who by definition meet the JNC 7 recommendation for initial combination antihypertensive therapy. Methods This multicenter, double-blind, 12-week study randomized 364 patients with stage 2 hypertension to fixed-dose combination therapy with amlodipine besylate/benazepril HCl (5/20 mg/d titrated to 10/20 mg/d) or amlodipine besylate monotherapy (5 mg/d titrated to 10 mg/d). Results Significantly more patients randomized to combination therapy (74.2%) compared with those randomized to monotherapy (53.9%; P< .0001) achieved the primary end point (reductions in systolic BP ≥25 mm Hg, if baseline systolic BP was <180 mm Hg, or ≥32 mm Hg, if baseline systolic BP was ≥180 mm Hg). Significantly more patients randomized to combination therapy compared with monotherapy attained BP goals of <140/90 mm Hg (61.0% v 43.3%; P = .0007) and ≤130/85 mm Hg (35.7% v 19.1%; P = .0004). Among patients with baseline systolic BP ≥180 mm Hg, combination therapy resulted in significantly greater reductions in systolic BP compared with monotherapy (−42.3 v −30.4 mm Hg; P = .001). More than 90% of patients in each group were titrated to the higher dose. Both treatments were well tolerated. Conclusions Combination therapy was well tolerated and resulted in significantly greater BP reductions and attainment of BP goals compared with monotherapy in patients with stage 2 hypertension. This evidence supports the recommendation of combination therapy as first-line treatment in stage 2 hypertension.